Eli Lilly | LLY - Current Assets


Eli Lilly reported $64.67B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Abbott USD 25.51B 488M Mar/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Baxter International USD 6.99B 142M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Drreddys Laboratories INR 301.98B 298.66B Mar/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
J&J USD 56.35B 3.42B Sep/2026
Medtronic USD 24.39B 397M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Perrigo USD 2.45B 260.7M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Phibro Animal Health USD 935.51M 41.44M Jun/2026
Prestige Brands USD 496.81M 65.33M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Sanofi EUR 30.16B 789M Mar/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
Zoetis USD 6.36B 118M Jun/2026